Key Findings:  Cannabidiol is associated with clinical improvement in children with Dravet syndrome. However, it was also associated with decreased appetite, and possibly adverse mental events.
Type of Study:  Meta-analysis
Study Sample Size:  8
Study Result:  Positive
Study Location(s):  Belgium, Israel, Netherlands
Year of Pub:  2021
Cannabinoids Studied:  Cannabidiol (CBD), Cannabinoid (unspecified), Pharma THC, Pharma THC:CBD, Pharma CBD, Tetrahydrocannabivarin (THCV)
Phytocannabinoid Source:  Not Applicable
DOSING DETAILS   
Study Dosing Objective:  Effective Dose, Safety Profile
Established Protocol:  Effective dose with adverse effects
Cannabinoid Ratio:  (Pharma CBD : Pharma THC : Pharma THC:CBD)   0 : 0 : 0    
Clinical Relevance:  Cannabidiol is associated with a 50% reduction in seizure rate, clinical improvement in Dravat syndrome, and caregiver global impression of change, but may also reduce appetite.
Adverse Events:  20 mg/kg/d CBD results in a significant, elevated risk for decreased appetite 10 mg/kg/d might result in a mild elevation in the risk